Decision: Favourable
Study Title:
A Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME-401) in Combination with Rituximab Versus Standard Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin’s Lymphoma (iNHL) – The COASTAL Study
NREC Code:
21-NREC-CT-046-NCP
Decision:
Favourable
Meeting Date:
11/08/2021
Study Type:
CT application
Principal Investigator:
Elisabeth Vandenberghe
PI Institution:
St James's Hospital
Sponsor:
Parexel International (IRL) Limited